Citreoviridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: Citreoviridine
• 英文别名: 6-[(1E,3E,5E,7E)-8-(3,4-dihydroxy-2,4,5-trimethyloxolan-2-yl)-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one
• 化学式: C₂₃H₃₀O₆
• 分子量: 402.5
• InChiKey: JLSVDPQAIKFBTO-USJRQALFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

ADMET

毒理性

• 毒性总结

柑橘绿霉素抑制膜结合和可溶性的线粒体ATP酶。尤其是，它抑制突触体Na+/K+-ATP酶，改变突触传递，并与F1-ATP酶的beta亚单位结合。因此，它已被证明可以抑制线粒体能量相关反应，如ADP刺激的呼吸、ATP驱动的琥珀酸还原NAD+和ATP驱动的NAD转移酶。霉菌毒素通常能够通过人类有机阴离子转运体（hOATs）和人类有机阳离子转运体（hOCTs）进入肝脏和肾脏。它们还可以抑制这些转运体的阴离子和阳离子摄取，干扰内源代谢物、药物和外源性物质（包括它们自身）的分泌。这导致细胞内毒性化合物的积累增加，引起肾毒性和肝毒性。（A3002，A3003，A3005，A3006，A3014）

Citreoviridin inhibits both membrane-bound and soluble mitochondrial ATPases. In particular, it inhibits synaptosomal Na+/K+-ATPase, altering synaptic transmission, and binds to the beta subunit of F1-ATPAse. As a result it has been shown to inhibit mitochondrial energy-linked reactions such as ADP-stimulated respiration, ATP-driven reduction of NAD + by succinate, and ATP-driven NAD transhydrogenase. Mycotoxins are often able to enter the liver and kidney by human organic anion transporters (hOATs) and human organic cation transporters (hOCTs). They can also inhibit uptake of anions and cations by these transporters, interfering with the secretion of endogenous metabolites, drugs, and xenobiotics including themselves. This results in increased cellular accumulation of toxic compounds causing nephro- and hepatotoxicity. (A3002, A3003, A3005, A3006, A3014)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌物分类

对人类不具有致癌性（未被国际癌症研究机构IARC列名）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 健康影响

Citreoviridin 选择性地抑制延髓中的运动神经细胞，并在灰质和脑干中积累。这可能导致中枢神经系统抑制，进而引起呼吸和心血管衰竭以及死亡。

Citreoviridin selectively inhibits motor nerve cells in the medulla oblongata and accumulates in the grey matter and brain stem. This can cause central nervous system depression leading to respiratory and cardiovascular failures and death. (A3002, A3004, A3005)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 暴露途径

口服、皮肤、吸入和 parenteral（被污染的药物）。 (A3101)

Oral, dermal, inhalation, and parenteral (contaminated drugs). (A3101)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 症状

绿脓素暴露的症状包括进行性瘫痪、呕吐、抽搐和逐渐加重的呼吸障碍。(A3002)

Symptoms of citreoviridin exposure include progressive paralysis, vomiting, convulsions, and gradual respiratory disorder. (A3002)

来源:Toxin and Toxin Target Database (T3DB)